KROS · Keros Therapeutics Inc
United States · RS rating 44 · As of 2026-10-14
| Price | 11.05 USD |
|---|---|
| 1-day change | -1.6% |
| RS rating (overall / 1M / 3M / 12M) | 44 / 60 / 79 / 21 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 16 / 14 / 19 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -377.8% |
| Sales growth Q/Q | -97.3% |
| Distance from 52-week high | +49.4% |
| Market cap (USD) | $228.7M |